Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$784.00K$784.00Kderived−13.8% vs Q4 2020 Net Income-$1.79M-$1.79MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$320,000−31.5% Operating Incomederived-$1,763,000N/M Operating Cash Flowderived-$975,000N/M Margins · derivedGross margin40.8%−10.6 pt vs Q4 2020
Operating margin-224.9%−8.5 pt vs Q4 2020
Net margin-228.4%−9.1 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 31, 2022 · 90 d after period end